ACOR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (11 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	321 668
Vidutinė apimtis	139 878
Rinkos kapitalizacija	821 028
EPS	$0 ( 2024-04-01 )
Kita pelno data	( $0 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0120 (1.96%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-22	Burns Thomas M.	Buy	2 400	Non-Employee Stock Option
2023-06-22	Burns Thomas M.	Buy	0
2023-06-22	Varian John	Buy	1 200	Non-Employee Stock Option
2023-06-22	Panem Sandra Phd	Buy	1 200	Non-Employee Stock Option
2023-06-22	Kelley John P	Buy	1 200	Non-Employee Stock Option

INSIDER POWER
99.33
Last 96 transactions
Buy: 1 532 806 \| Sell: 94 790

Tūris Koreliacija

Ilgas: -0.43 (neutral)

Trumpas: -0.79 (moderate negative)

Signal:(18.947) Neutral

Acorda Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
HCTI	0.95
TVTX	0.945
ALBO	0.939
MNST	0.934
CMPI	0.93
GNLN	0.929
APLT	0.929
MORF	0.924
SBET	0.922
UFO	0.922

10 Labiausiai neigiamai susiję koreliacijos
NTGR	-0.928
PI	-0.928
ATRS	-0.919
PPBT	-0.916
HONE	-0.912
CPSI	-0.912
BRAC	-0.908
KDNY	-0.907
MSAC	-0.903
LGTO	-0.901

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Acorda Therapeutics Inc Koreliacija - Valiuta/Žaliavos

0.17
( neutral )

0.12
( neutral )

0.37
( neutral )

0.61
( weak )

0.32
( neutral )

Acorda Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$117.63M
Bruto pelnas:	$71.59M (60.86 %)
EPS:	$-203.59

FY	2023
Pajamos:	$117.63M
Bruto pelnas:	$71.59M (60.86 %)
EPS:	$-203.59

FY	2022
Pajamos:	$118.57M
Bruto pelnas:	$88.23M (74.42 %)
EPS:	$-66.90

FY	2021
Pajamos:	$129.07M
Bruto pelnas:	$88.28M (68.40 %)
EPS:	$-12.86

Financial Reports:

No articles found.

Acorda Therapeutics Inc

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Realaus laiko atnaujinimai Acorda Therapeutics Inc [ACOR]

Upcoming Earnings Alert